Analyst Price Target is $197.67
▲ +113.05% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Allakos in the last 3 months. The average price target is $197.67, with a high forecast of $230.00 and a low forecast of $145.00. The average price target represents a 113.05% upside from the last price of $92.78.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Allakos. This rating has held steady since December 2020, when it changed from a Hold consensus rating.
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.